Key Metabolic Functions of β-Arrestins: Studies with Novel Mouse Models

Overview

Journal Trends Endocrinol Metab

Specialty Endocrinology

Date 2020 Dec 28

PMID 33358450

Citations 5

Authors

Sai P Pydi

Luiz F Barella

Jaroslawna Meister

Jurgen Wess

Affiliations

Soon will be listed here.

Abstract

β-Arrestin-1 and -2 are intracellular proteins that are able to inhibit signaling via G protein-coupled receptors (GPCRs). However, both proteins can also modulate cellular functions in a G protein-independent fashion. During the past few years, studies with mutant mice selectivity lacking β-arrestin-1 and/or -2 in metabolically important cell types have led to novel insights into the mechanisms through which β-arrestins regulate key metabolic processes in vivo, including whole-body glucose and energy homeostasis. The novel information gained from these studies should inform the development of novel drugs, including β-arrestin- or G protein-biased GPCR ligands, that could prove useful for the therapy of several important pathophysiological conditions, including type 2 diabetes and obesity.

Citing Articles

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.

Sztanek F, Toth L, Peto A, Hernyak M, Dioszegi A, Harangi M Biomedicines. 2024; 12(6).

PMID: 38927527 PMC: 11201978. DOI: 10.3390/biomedicines12061320.

Hepatic β-arrestins: potential roles in liver health and disease.

Eissa A, Hassanin M, Ibrahim I Mol Biol Rep. 2023; 50(12):10399-10407.

PMID: 37843713 PMC: 10676313. DOI: 10.1007/s11033-023-08898-0.

β-arrestin1 regulates astrocytic reactivity via Drp1-dependent mitochondrial fission: implications in postoperative delirium.

Hua F, Zhu H, Yu W, Zheng Q, Zhang L, Liang W J Neuroinflammation. 2023; 20(1):113.

PMID: 37170230 PMC: 10173541. DOI: 10.1186/s12974-023-02794-x.

Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity.

Oliveira de Souza C, Sun X, Oh D Front Endocrinol (Lausanne). 2021; 12:715877.

PMID: 34497585 PMC: 8419444. DOI: 10.3389/fendo.2021.715877.

Designer GPCRs as Novel Tools to Identify Metabolically Important Signaling Pathways.

Wess J Front Endocrinol (Lausanne). 2021; 12:706957.

PMID: 34354673 PMC: 8329487. DOI: 10.3389/fendo.2021.706957.

References

Cavalcanti-de-Albuquerque J, Bober J, Zimmer M, Dietrich M . Regulation of substrate utilization and adiposity by Agrp neurons. Nat Commun. 2019; 10(1):311. PMC: 6338802. DOI: 10.1038/s41467-018-08239-x. View

Urs N, Gee S, Pack T, McCorvy J, Evron T, Snyder J . Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci U S A. 2016; 113(50):E8178-E8186. PMC: 5167191. DOI: 10.1073/pnas.1614347113. View

Steculorum S, Ruud J, Karakasilioti I, Backes H, Engstrom Ruud L, Timper K . AgRP Neurons Control Systemic Insulin Sensitivity via Myostatin Expression in Brown Adipose Tissue. Cell. 2016; 165(1):125-138. PMC: 5157157. DOI: 10.1016/j.cell.2016.02.044. View

Pydi S, Jain S, Tung W, Cui Y, Zhu L, Sakamoto W . Adipocyte β-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. Nat Commun. 2019; 10(1):2936. PMC: 6610117. DOI: 10.1038/s41467-019-11003-4. View

Kim J, Grotegut C, Wisler J, Li T, Mao L, Chen M . β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility. Skelet Muscle. 2018; 8(1):39. PMC: 6309084. DOI: 10.1186/s13395-018-0184-8. View

Pydi S, Jain S, Barella L, Zhu L, Sakamoto W, Meister J . β-arrestin-1 suppresses myogenic reprogramming of brown fat to maintain euglycemia. Sci Adv. 2020; 6(23):eaba1733. PMC: 7274797. DOI: 10.1126/sciadv.aba1733. View

Tian X, Kang D, Benovic J . β-arrestins and G protein-coupled receptor trafficking. Handb Exp Pharmacol. 2013; 219:173-86. PMC: 4513654. DOI: 10.1007/978-3-642-41199-1_9. View

Saltiel A, Olefsky J . Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017; 127(1):1-4. PMC: 5199709. DOI: 10.1172/JCI92035. View

Scherer P . The many secret lives of adipocytes: implications for diabetes. Diabetologia. 2018; 62(2):223-232. PMC: 6324990. DOI: 10.1007/s00125-018-4777-x. View

10.

Unger R, Cherrington A . Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012; 122(1):4-12. PMC: 3248306. DOI: 10.1172/JCI60016. View

11.

Dadi P, Vierra N, Ustione A, Piston D, Colbran R, Jacobson D . Inhibition of pancreatic β-cell Ca2+/calmodulin-dependent protein kinase II reduces glucose-stimulated calcium influx and insulin secretion, impairing glucose tolerance. J Biol Chem. 2014; 289(18):12435-45. PMC: 4007438. DOI: 10.1074/jbc.M114.562587. View

12.

Gurevich V, Gurevich E . Biased GPCR signaling: Possible mechanisms and inherent limitations. Pharmacol Ther. 2020; 211:107540. PMC: 7275904. DOI: 10.1016/j.pharmthera.2020.107540. View

13.

Sato M, Dehvari N, Oberg A, Dallner O, Sandstrom A, Olsen J . Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes. 2014; 63(12):4115-29. DOI: 10.2337/db13-1860. View

14.

Peterson Y, Luttrell L . The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling. Pharmacol Rev. 2017; 69(3):256-297. PMC: 5482185. DOI: 10.1124/pr.116.013367. View

15.

Takahashi T, Shibasaki T, Takahashi H, Sugawara K, Ono A, Inoue N . Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013; 6(298):ra94. DOI: 10.1126/scisignal.2004581. View

16.

Pocai A, Lam T, Gutierrez-Juarez R, Obici S, Schwartz G, Bryan J . Hypothalamic K(ATP) channels control hepatic glucose production. Nature. 2005; 434(7036):1026-31. DOI: 10.1038/nature03439. View

17.

Xiao K, McClatchy D, Shukla A, Zhao Y, Chen M, Shenoy S . Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A. 2007; 104(29):12011-6. PMC: 1913545. DOI: 10.1073/pnas.0704849104. View

18.

Sriram K, Insel P . G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?. Mol Pharmacol. 2018; 93(4):251-258. PMC: 5820538. DOI: 10.1124/mol.117.111062. View

19.

Ceddia R, Collins S . A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure. Clin Sci (Lond). 2020; 134(5):473-512. PMC: 9137350. DOI: 10.1042/CS20190579. View

20.

DeFronzo R, Tripathy D . Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009; 32 Suppl 2:S157-63. PMC: 2811436. DOI: 10.2337/dc09-S302. View